Literature DB >> 20673745

The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Kaori Shinoda1, Linda S Wyatt, Bernard Moss.   

Abstract

The vaccinia virus (VACV) entry-fusion complex (EFC) is composed of at least nine membrane proteins. Immunization of mice with individual EFC genes induced corresponding protein-binding antibody but failed to protect against VACV intranasal challenge and only DNA encoding A28 elicited low neutralizing antibody. Because the A28 and H2 proteins interact, we determined the effect of immunizing with both genes simultaneously. This procedure greatly enhanced the amount of antibody that bound intact virions, neutralized infectivity, and provided partial protection against respiratory challenge. Neither injection of A28 and H2 plasmids at different sites or mixing A28 and H2 sera enhanced neutralizing antibody. The neutralizing antibody could be completely removed by binding to the A28 protein alone and the epitope was located in the C-terminal segment. These data suggest that the interaction of H2 with A28 stabilizes the immunogenic form of A28, mimicking an exposed region of the entry-fusion complex on infectious virions. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673745      PMCID: PMC2914698          DOI: 10.1016/j.virol.2010.05.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  63 in total

1.  DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.

Authors:  J W Hooper; D M Custer; C S Schmaljohn; A L Schmaljohn
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

2.  Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

3.  A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate.

Authors:  C S Chung; J C Hsiao; Y S Chang; W Chang
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

4.  A vaccinia serine protease inhibitor which prevents virus-induced cell fusion.

Authors:  K M Law; G L Smith
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

5.  The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus.

Authors:  Peter C Turner; Richard W Moyer
Journal:  Virology       Date:  2008-08-28       Impact factor: 3.616

6.  Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses.

Authors:  P S Satheshkumar; Bernard Moss
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

7.  New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.

Authors:  Alexandre Borovkov; D Mitch Magee; Andrey Loskutov; Jose A Cano; Cheryl Selinsky; Jason Zsemlye; C Rick Lyons; Kathryn Sykes
Journal:  Virology       Date:  2009-10-02       Impact factor: 3.616

8.  Immunity from smallpox vaccine persists for decades: a longitudinal study.

Authors:  Dennis D Taub; William B Ershler; Mark Janowski; Andrew Artz; Michael L Key; Julie McKelvey; Denis Muller; Bernard Moss; Luigi Ferrucci; Patricia L Duffey; Dan L Longo
Journal:  Am J Med       Date:  2008-12       Impact factor: 4.965

9.  Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Authors:  Kaori Shinoda; Linda S Wyatt; Kari R Irvine; Bernard Moss
Journal:  Virol J       Date:  2009-03-03       Impact factor: 4.099

Review 10.  The immunology of smallpox vaccines.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Curr Opin Immunol       Date:  2009-06-11       Impact factor: 7.486

View more
  7 in total

1.  T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.

Authors:  D Huw Davies; Sookhee Chun; Gary Hermanson; Jo Anne Tucker; Aarti Jain; Rie Nakajima; Jozelyn Pablo; Philip L Felgner; Xiaowu Liang
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

Review 2.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 3.  Membrane fusion during poxvirus entry.

Authors:  Bernard Moss
Journal:  Semin Cell Dev Biol       Date:  2016-07-14       Impact factor: 7.727

4.  Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

Authors:  M B Townsend; M S Keckler; N Patel; D H Davies; P Felgner; I K Damon; K L Karem
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

Review 5.  Poxvirus cell entry: how many proteins does it take?

Authors:  Bernard Moss
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

Review 6.  The strategic use of novel smallpox vaccines in the post-eradication world.

Authors:  Joseph W Golden; Jay W Hooper
Journal:  Expert Rev Vaccines       Date:  2011-07       Impact factor: 5.683

Review 7.  A comparative review of viral entry and attachment during large and giant dsDNA virus infections.

Authors:  Haitham Sobhy
Journal:  Arch Virol       Date:  2017-09-02       Impact factor: 2.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.